Sironax

Executive Summary

Sironax is a US-based private biotech company founded in 2021, focused on developing novel therapeutics targeting cellular senescence and regenerative pathways to address age-related diseases. The company's pipeline emphasizes ophthalmology and neurodegenerative conditions, aiming to modify fundamental aging processes and restore tissue function. With $200 million raised, Sironax is in Phase 1 development, leveraging its proprietary platform to identify and advance small molecules and biologics that combat senescence. The company's approach has the potential to address large unmet medical needs in aging populations, but it remains early-stage with no approved products. Sironax's progress in preclinical and early clinical studies will be critical to validating its platform and attracting further investment or partnerships. The company is headquartered in Cambridge, MA, and employs 50-200 people, reflecting a focused research organization.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 clinical data readout for lead ophthalmology candidate40% success
• Q4 2026IND submission for neurodegenerative program60% success
• TBDPotential partnership or collaboration announcement for senescence platform45% success